Walder Wyss advised SkyCell on its USD 116 million Series D financing round. It embarked on a USD 57 million equity investment by M&G Investments in October 2023 and has now been completed with further investments
Vischer advised Mininavident, located in Liestal, a developer and manufacturer of the world’s smallest dynamic navigation system for dental implant placement, which was acquired by the Straumann Group, a global leader in tooth replacement,
Homburger advised Danaher Corporation on its acquisition of Genedata, advised by Vischer, which on August 19th, 2024, announced that it had been acquired by Danaher Corporation (NYSE: DHR), a global life science and diagnostic innovator. Homburger
CMS has comprehensively advised Henry Schein, a provider of health care solutions to office-based dental and medical practitioners, on the acquisition of ABC Dental. MLL Legal advised ADMETOS on the sale of ABC Dental. The
Altenburger advised the Rey family with respect to the sale of a majority stake in the company REY Médical to Duomed group. This acquisition fits into Duomed’s strategy to grow as a distribution
An international CMS team under the lead of Stefan Brunnschweiler (pictured left) and Florian Jung (pictured right) provided comprehensive advice to Ypsomed on all legal aspects regarding the completion of the sale of its pen
Baker McKenzie advised KD Pharma Group, a global producer of pharmaceutical and nutritional lipids, on the acquisition of dsm-firmenich’s marine lipids business in exchange for a minority stake in KD Pharma Group. The transaction
Advestra advised UBS Switzerland as mandated lead arranger, coordinator, agent, security agent and lender together with the other syndicate banks as lenders on the EUR 200 mil
BGPartner advised Novo Holdings, EQT, OrbiMed and SR One on $100 million Series C financing of Swiss biotech company Asceneuron, represented by Lenz & Staehelin, Geneva. The financing round was led by Novo Holdings with new
Baker McKenzie advised CureVac, a global biopharmaceutical company developing transformative medicines based on messenger ribonucleic acid (mRNA), on restructuring its existing collaboration with GSK into a new licensing agreement, allowing each company to prioritize investment
